Acenocoumarol anticoagulant

Description Results

Acenocoumarol INR 2-4.5 (n=72)

vs.

Placebo (n=74)

Simple aveugle

Factorial plan

Sample size: 72/74

Primary endpoint: Périmètre de marche

FU duration: 1 an

major hemorrhage 1.60 [0.38; 6.82]

clinical PE NaN [NaN; NaN]

DVT 1.18 [0.81; 1.70]

proximal DVT 0.89 [0.46; 1.75]

major hemorrhage 3.89 [1.20; 12.64]

Death ∞ [NaN; ∞]

clinical PE ∞ [NaN; ∞]

DVT 1.35 [0.70; 2.61]

proximal DVT 1.35 [0.30; 6.00]

Acenocoumarol (n=342)

vs.

Nadroparin 60 anti-Xa IU /kg x1 (n=330)

single blind

Sample size: 342/330

Primary endpoint:

FU duration: Day 10 ± 2

Acenocoumarol (n=645)

vs.

Reviparin 4200 anti-Xa IU x1 (n=644)

Open

Sample size: 645/644

Primary endpoint:

FU duration: 6 weeks

Acenocoumarol (n=11)

vs.

UFH 4000 ·x2 (n=11)

double blind

Sample size: 11/11

Primary endpoint:

FU duration: NA